1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Clinical features, disease stage, final nodal size (relative to baseline CT), and patient outcome
Patient No.Lesion No.Age, yrSexStageBRAF StatusLocationFinal Lesion SizePatient Outcome
1163FT3bN3M1aNegativeLeft supraclavicularDecreasedRemission.
2266MTxNxM1cWild typeRight supraclavicularDecreasedT-VEC discontinued after disease progression in ribs. Placed on nivolumab with partial response.
3Right supraclavicularDecreased
3440MpT1bN3M1cPositiveRight preauricularDecreasedIL-2 followed by BRAF and MEK inhibitors after ipilimumab/T-VEC treatment. Deceased.
5Right submandibularDecreased
4644MT3bN3M1bPositiveRight axillaryDecreasedBRAF and MEK inhibitors after ipilimumab/T-VEC treatment, followed by disease progression. Deceased.
7Right axillaryDecreased
5858FT3bN2M1aWild typeLeft upper backDecreasedComplete response for 21 months, followed by axillary recurrence. Placed on nivolumab.
9Left breastDecreased
61032MT4bN3M1aNegativeLeft retroauricularDecreasedPartial response for 6 months. Placed on nivolumab.
71163MT3aN3M1cNegativeRight chest wallIncreasedRapid deterioration after brain metastases. Deceased.
12Right axillaDecreased
  • Note:—IL-2 indicates interleukin 2.